How to Get Zetia (Ezetimibe) in Virginia

What Is Zetia and Why Is It Prescribed?

Ezetimibe (Zetia) is an oral cholesterol-absorption inhibitor that the FDA approved in 2002 for adults with primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia [1]. The drug blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, cutting dietary and biliary cholesterol absorption by roughly 50% [2]. As monotherapy, ezetimibe typically lowers LDL-C by 18 to 20% [3]. Combined with a statin, it can produce an additional 25% reduction on top of statin-only results.

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol specifically recommends adding ezetimibe when a maximally tolerated statin fails to reach the LDL-C goal in high- and very-high-risk patients [4]. That guideline states: "In patients with clinical ASCVD, ezetimibe may be added to maximally tolerated statin therapy when LDL-C remains above threshold goals." Virginia physicians routinely follow the 2018 ACC/AHA guidance, and telehealth providers in the state apply the same standard of care.

Ezetimibe is generally well-tolerated. The most commonly reported side effects in clinical trials were upper respiratory infection (4.3%), diarrhea (4.1%), and arthralgia (3.0%) [1]. Liver enzyme elevations above three times the upper limit of normal were rare when ezetimibe was used without a statin.

The IMPROVE-IT Trial: The Clinical Evidence Behind Ezetimibe

The landmark IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 answered a decade-long debate about whether adding ezetimibe to statin therapy produced real cardiovascular benefit beyond LDL lowering alone [5]. Patients with recent acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo.

Over a median follow-up of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-only group [5]. The primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) occurred in 32.7% of patients in the combination group versus 34.7% in the placebo group, an absolute risk reduction of 2.0 percentage points and a 6.4% relative risk reduction (P<0.016) [5]. This was the first trial to demonstrate that a non-statin lipid-lowering agent added on top of a statin actually reduces hard cardiovascular events in high-risk patients.

Diabetic patients in the IMPROVE-IT subgroup showed an even larger absolute benefit, with a 5.5 percentage-point reduction in major adverse cardiovascular events [5]. These findings directly informed the 2018 ACC/AHA guideline's Class IIa recommendation for adding ezetimibe in very-high-risk ASCVD patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [4].

The HealthRX clinical team uses the following decision framework for Virginia patients considering ezetimibe:

HealthRX Ezetimibe Access Framework (Virginia)

1. Confirm LDL-C threshold. Patients with clinical ASCVD and LDL-C at or above 70 mg/dL on maximally tolerated statin are the primary candidates per the 2018 ACC/AHA guideline [4].
2. Rule out secondary causes. Obtain TSH, fasting glucose, and a basic metabolic panel to exclude hypothyroidism, diabetes, or renal disease driving elevated LDL.
3. Assess statin tolerance. If the patient is statin-intolerant, ezetimibe monotherapy is a reasonable first-line option, consistent with the ACC/AHA's statin-intolerance pathway [4].
4. Choose prescribing pathway. Virginia allows telehealth prescribing; a single asynchronous or synchronous visit with chart review of recent labs (within 12 months) is sufficient for most commercial insurers.
5. Identify pharmacy. Generic ezetimibe is available at all major Virginia retail chains and through mail-order; 503A compounders are an option only when a commercially available product is not appropriate.

How to Get a Zetia Prescription in Virginia

Getting a Zetia prescription in Virginia follows the same basic path as any other prescription-only medication. You need a licensed prescriber to evaluate your cholesterol history, review current medications, and determine that ezetimibe is appropriate. Virginia Code §54.1-3303 requires a valid practitioner-patient relationship before a prescription can be issued.

Option 1: In-person visit. Your primary care physician or a cardiologist in Virginia can prescribe ezetimibe at any routine office visit. Bring your most recent lipid panel (ideally within 6 months) and a list of current medications. Statins, bile acid sequestrants, and fibrates all have potential interactions or overlapping indications that your provider will want to review.

Option 2: Telehealth visit. Virginia enacted permanent telehealth parity legislation that took full effect in 2021 under Va. Code §38.2-3418.16, requiring commercial insurers to reimburse telehealth visits at the same rate as in-person care. Controlled substances require a DEA-registered provider with a prior in-person exam, but ezetimibe is not a controlled substance, so it can be prescribed after a synchronous video visit or, with some platforms, an asynchronous questionnaire review. Several national telehealth platforms and state-licensed Virginia providers offer cardiology and primary care consultations that can result in a same-day ezetimibe prescription.

Option 3: HealthRX telehealth. HealthRX is licensed to serve Virginia patients. After completing an intake form and uploading recent labs, a board-certified provider reviews your case and can issue a prescription electronically to any Virginia pharmacy you choose. Most patients complete this process in under 24 hours on business days.

What Labs Are Required Before Starting Ezetimibe in Virginia?

A fasting lipid panel is the baseline test every prescriber will want before starting ezetimibe. Most Virginia providers and telehealth platforms also ask for liver function tests (AST, ALT) because the FDA label for Zetia notes that liver enzyme abnormalities have occurred, particularly when ezetimibe is combined with a statin [1]. A baseline creatine kinase (CK) level is reasonable if you are simultaneously starting or continuing a statin, given the small risk of myopathy [6].

The ACC/AHA 2018 guideline recommends checking a fasting lipid panel 4 to 12 weeks after starting or adjusting lipid-lowering therapy to confirm the expected LDL-C response [4]. For ezetimibe added to statin therapy, expect LDL-C to fall by an additional 15 to 25 mg/dL. Labs should repeat at 3 months, then annually if the patient is stable.

Thyroid-stimulating hormone (TSH) is not required by any guideline before prescribing ezetimibe, but hypothyroidism is a common secondary cause of elevated LDL-C in Virginia's adult population, and identifying it early avoids years of unnecessary lipid-lowering therapy [7]. Many Virginia providers add TSH to the initial workup as a practical precaution.

Specific lab values that will usually satisfy a Virginia telehealth prescriber for a same-day prescription:

• Fasting lipid panel within 12 months (LDL-C, HDL-C, TG, total cholesterol)
• AST and ALT within 12 months
• Basic metabolic panel (to assess renal function and glucose)
• CK level if concurrently on a statin (within 12 months)

Telehealth Providers in Virginia Prescribing Ezetimibe

Virginia is one of the more telehealth-friendly states in the Southeast. The Virginia Telehealth Alliance reports that more than 2.3 million telehealth visits occurred in Virginia during 2022 alone [8]. Cardiology and primary care make up the two largest telehealth specialties in the state.

Any telehealth provider licensed in Virginia (MD, DO, NP, or PA) can prescribe ezetimibe, as it is a non-controlled oral medication. Platforms that serve Virginia include national services such as Teladoc, MDLive, and Amazon Clinic, as well as cardiology-focused services. HealthRX operates under Virginia licensure and specializes in cardiometabolic conditions including hyperlipidemia.

For synchronous video visits, most platforms offer appointments within 24 to 48 hours. Asynchronous (store-and-forward) visits, where you complete a questionnaire and upload labs, can result in a prescription the same day. Virginia's Board of Medicine (18 VAC 85-20-26) permits asynchronous prescribing for non-controlled substances when the provider can establish a sufficient clinical picture from submitted records.

Ezetimibe Pharmacies in Virginia: Retail, Mail-Order, and 503A Compounders

Retail pharmacies. Generic ezetimibe 10 mg is stocked at every major Virginia retail pharmacy, including CVS, Walgreens, Walmart, Kroger, and Rite Aid. The GoodRx price for a 30-day supply of generic ezetimibe 10 mg at Virginia pharmacies typically runs between $15 and $35 without insurance. Brand-name Zetia costs considerably more (often above $300 per month) without insurance or manufacturer coupons.

Mail-order pharmacies. Express Scripts, CVS Caremark, and OptumRx all ship to Virginia addresses. Standard processing plus shipping takes 3, 7 business days after prescription verification. Most Virginia commercial insurance plans incentivize 90-day mail-order supply fills, which can lower the per-unit cost further.

503A compounding pharmacies. Virginia-licensed 503A compounding pharmacies can legally prepare ezetimibe preparations when a prescriber documents a clinical need that the commercially available product cannot meet, such as a patient requiring a lower dose (e.g., 5 mg) for tolerability [9]. The FDA's guidance on 503A pharmacies specifies that compounded preparations must be made pursuant to a valid patient-specific prescription [9]. The standard commercially available 10 mg tablet is appropriate for the vast majority of patients; compounding is not appropriate simply for cost savings.

Virginia Medicaid Coverage and Prior Authorization for Zetia

Virginia Medicaid (Medallion 4.0 and Cardinal Care) covers generic ezetimibe for hyperlipidemia as an adjunct to diet and statin therapy, but prior authorization (PA) is required [10]. The PA criteria generally ask the prescriber to document:

• A diagnosis of primary hyperlipidemia, mixed hyperlipidemia, or homozygous familial hypercholesterolemia
• An adequate trial of a statin (typically 90 days or documentation of statin intolerance)
• A current LDL-C level and a target that ezetimibe is expected to help meet
• Any relevant ASCVD history supporting high- or very-high-risk classification

Most Virginia prescribers complete the PA form through the CoverMyMeds portal or directly through the MCO's web portal. Turnaround is typically 1, 3 business days for standard PA and within 24 hours for urgent or expedited PA requests. Patients who are denied can request a formulary exception or an appeal; the 2018 ACC/AHA guideline documentation of a Class IIa recommendation is often sufficient clinical justification [4].

Commercial insurers in Virginia vary widely. Many Anthem, Aetna, and UnitedHealthcare plans cover generic ezetimibe on Tier 1 or Tier 2 with a copay of $5, $30 per month. Patients whose plans place ezetimibe on Tier 3 or above should ask their prescriber to submit a step-edit exception citing documented statin-only inadequacy.

Transferring a Zetia Prescription to Virginia

Transferring a prescription from another state to a Virginia pharmacy is straightforward for non-controlled substances. Federal law and Virginia Board of Pharmacy regulations allow a pharmacist to accept a transferred prescription from a licensed pharmacy in any other U.S. state [11]. The receiving pharmacy calls or electronically contacts the originating pharmacy to transfer the remaining refills.

For patients moving to Virginia from another state mid-supply, most pharmacies allow one transfer of the remaining authorized refills. The prescription cannot be transferred again after that first transfer (Virginia Board of Pharmacy Regulation 18 VAC 110-20-270). If refills are exhausted, a new prescription from a Virginia-licensed provider is required.

One practical note: if you have an active prescription at an out-of-state pharmacy that is part of a national chain (CVS, Walgreens, Walmart), you can often simply fill it at a Virginia location of the same chain without a formal transfer, because these chains maintain centralized prescription records accessible to any location.

Who Can Prescribe Zetia in Virginia?

Virginia allows a broad scope of practice for prescribers. The following clinician types are legally authorized to prescribe ezetimibe in Virginia:

Physicians (MD or DO). Full prescriptive authority. No collaborative practice agreement required [12].

Nurse Practitioners (NP). Virginia enacted full practice authority for NPs effective January 1, 2021, under Va. Code §54.1-2957.02. Certified NPs in Virginia can prescribe ezetimibe without a physician supervision agreement [12].

Physician Assistants (PA). PAs in Virginia prescribe under a written agreement with a supervising physician. They have full authority to prescribe non-controlled substances including ezetimibe within that agreement [12].

Clinical Nurse Specialists and Certified Nurse Midwives. These advanced practice nurses also hold prescriptive authority under Virginia Board of Nursing regulations and can prescribe ezetimibe within their scope.

Telehealth platforms operating in Virginia should confirm that the prescribing clinician holds a current Virginia license before issuing a prescription. Patients can verify any Virginia prescriber's license status at the Virginia Department of Health Professions license lookup portal.

How Long Until You Receive Zetia After a Virginia Telehealth Visit?

Timeline from telehealth consultation to medication in hand depends on the prescribing platform and pharmacy choice.

Same-day asynchronous telehealth visit with a prescription routed electronically to a local Virginia pharmacy: you can pick up your ezetimibe the same afternoon or evening in most cases. Most major chains process electronic prescriptions within 2 to 4 hours.

Synchronous video visit followed by electronic prescription: prescription typically reaches your pharmacy within 30 minutes of visit completion. Same-day pickup is realistic for visits completed before 5 PM.

Mail-order: add 3, 7 business days for standard shipping after the pharmacy verifies the prescription. Many mail-order pharmacies auto-verify electronic prescriptions within 24 hours.

Virginia Medicaid prior authorization adds 1, 3 business days if a PA is required and has not been preauthorized. Some telehealth platforms submit PA paperwork on behalf of patients as part of the visit.

Ezetimibe Dosing, Safety, and Drug Interactions

The standard adult dose approved by the FDA is ezetimibe 10 mg once daily, taken with or without food [1]. No dose adjustment is required for mild hepatic impairment or mild-to-moderate renal impairment. Ezetimibe is not recommended in moderate-to-severe hepatic impairment because of significantly increased drug exposure [1].

Key drug interactions to discuss with your Virginia prescriber:

• Cyclosporine: Co-administration increases ezetimibe AUC up to 12-fold. The combination requires close monitoring and is generally avoided [1].
• Bile acid sequestrants (cholestyramine, colesevelam): These agents reduce ezetimibe bioavailability by roughly 55% if taken simultaneously. Ezetimibe should be taken at least 2 hours before or 4 hours after a bile acid sequestrant [1].
• Fibrates (fenofibrate, gemfibrozil): Both can increase ezetimibe and cholesterol levels in bile, raising the theoretical risk of cholelithiasis. Gemfibrozil co-administration is not recommended [1].
• Statins: No clinically meaningful pharmacokinetic interaction; combination is the most common clinical use and is well-supported by IMPROVE-IT data [5].

Pregnancy safety: ezetimibe is FDA Pregnancy Category X when combined with a statin. As monotherapy, it is Pregnancy Category C. Virginia prescribers should confirm contraceptive plans in women of reproductive age before prescribing [1].

Ezetimibe vs. PCSK9 Inhibitors in Virginia: When Each Is Appropriate

Virginia patients with very high cardiovascular risk who remain above their LDL-C goal on maximally tolerated statin plus ezetimibe may be candidates for PCSK9 inhibitors (evolocumab or alirocumab). The FOURIER trial (N=27,564) demonstrated that evolocumab reduced LDL-C by 59% from a baseline of approximately 92 mg/dL over a median 2.2 years, reducing the composite primary endpoint by 15% (P<0.001) [13]. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced major adverse cardiovascular events by 15% versus placebo in post-ACS patients [14].

However, ezetimibe remains the preferred second-line agent before escalating to a PCSK9 inhibitor, largely because of cost. Generic ezetimibe costs $15, $35 per month. Evolocumab (Repatha) and alirocumab (Praluent) cost $500 to $600 per month without insurance, and Virginia Medicaid and most commercial payers require documented failure of ezetimibe before approving a PCSK9 inhibitor. The 2022 ACC Expert Consensus Decision Pathway recommends a trial of ezetimibe for at least 4 to 12 weeks before initiating a PCSK9 inhibitor in most patients [15].

Monitoring After Starting Ezetimibe

After your Virginia prescriber starts ezetimibe, schedule a follow-up lab check at 4 to 12 weeks to confirm the expected LDL-C reduction. If LDL-C drops by the anticipated 18 to 20% (monotherapy) or 15 to 25 mg/dL additional reduction (on statin background), the prescription is working as expected [3]. Annual lipid panels thereafter are standard [4].

Liver enzyme monitoring beyond baseline is not routinely required by the FDA label unless symptoms of liver disease develop [1]. Myopathy is rare with ezetimibe monotherapy. In IMPROVE-IT, the rate of myopathy was 0.2% in both the ezetimibe-plus-simvastatin and simvastatin-alone arms, confirming that ezetimibe adds no meaningful myopathy risk [5].

If LDL-C remains above goal after 12 weeks on ezetimibe plus maximally tolerated statin, discuss the PCSK9 inhibitor pathway with your provider. At that point, the clinical and cost justification for escalation is well-established under current ACC/AHA guidance [4].